India · Delayed Price · Currency is INR Krsnaa Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw modest revenue growth of 4% year-over-year, with strong cash flow from government receivable recovery and resilient margins despite expansion costs. Retail diagnostics grew 8x, and the Rajasthan project is expected to drive significant revenue by FY27.
-
Q2 FY26 saw 11% revenue growth and 18% EBITDA growth, with margins expanding to 29%. Retail business surged 60% quarter-on-quarter, now 8% of revenue, and is expected to reach 15-20% next year. Receivables remain elevated but are targeted to improve.
-
Q1 FY 2026 saw 13% revenue growth, 19% EBITDA growth, and 15% PAT growth, with retail revenue rising to 6% of total. The Rajasthan PPP contract expands scale, with full rollout in 6-9 months and material revenues from FY 2027. Margins and working capital remain strong.
Fiscal Year 2025
-
FY 2025 saw 16% revenue growth, 34% EBITDA growth, and 37% net profit growth, with margins expanding and a strong retail push. Receivable days are expected to normalize, and the company targets continued double-digit growth and margin improvement in FY 2026.
-
Q3 FY25 saw 10% YoY revenue growth and 50% net profit growth, despite temporary project delays. Retail expansion and asset-light models are set to drive future growth, with management confident in achieving 25% annual revenue growth guidance.
-
Q2 FY2025 saw 20% revenue growth and 87% PAT growth, with strong expansion in new states and robust operational efficiency. Strategic investments and partnerships are set to drive further growth, with guidance reaffirmed for 25% revenue growth and sustainable margins.
-
Q1 FY25 saw 22% revenue growth and 39% EBITDA growth, with strong expansion in radiology and pathology segments. Retail and PPP projects are driving network growth, while the company remains net debt-free and targets 25%+ revenue growth for FY25.